Memorial Day Weekend Forecast: ‘Severe’ Storms, Tornadoes, ‘Sweltering’ Heat And Cool Conditions—Here’s What To Expect In Your Region
Eli Lilly will invest an additional $5.3 billion into a new manufacturing site, boosting production for its weight loss and diabetes medications Mounjaro and Zepbound, the pharmaceutical firm said Friday, as demand for the popular drugs has resulted in shortages.
The investment will add 200 full-time jobs at the site, including positions for engineers, scientists, operating personnel and lab technicians, bringing the total workforce at the site to 900 full-time employees, according to Eli Lilly. Production at the site is expected to begin toward the end of 2026, Eli Lilly said, with escalated operations through 2028.We’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines. Text “Alerts” to 335-0739 or sign upThe $5.3 billion is the largest manufacturing investment in Eli Lilly’s 150-year history, chief executive David Ricks said in a statement.$18 billion.